Tafenoquine Shows Promise in First Babesiosis Patient Study
60 Degrees Pharmaceuticals reported the first negative post-treatment result in its expanded access study of tafenoquine for relapsing babesiosis...
eClinical Tech News
Regeneron Spotlights Oncology Advances for Tough Cancers
Regeneron will present seven oncology abstracts at ESMO 2025, led by new Phase 3 C-POST safety and pharmacokinetic data...
Bexorg’s Revolutionary AI Platform for CNS gets $42.5M
Bexorg has closed a $23 million Series A led by Engine Ventures, bringing total funding to $42.5 million to...
argenx to Highlight Immunology Data at 2025 AANEM & MGFA
Argenx is using the AANEM Annual Meeting and MGFA Scientific Session to widen the runway for its neuromuscular franchise....
BioCryst’s Surging HAE Focus With Astria Therapeutics Deal
BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal valuing Astria at an implied $13.00 per share, or...
Salarius Pharmaceuticals’ Successful Nasdaq Compliance Victory
Salarius Pharmaceuticals has regained compliance with Nasdaq’s equity standard, completing its return to full listing compliance after previously restoring...
Rentschler Biopharma Sees Progress on New Laupheim Facility
Rentschler Biopharma is building a new buffer media station at its Laupheim, Germany headquarters, the largest single investment the...
Libtayo Approved as First Adjuvant Immunotherapy for CSCC
FDA has approved Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC)...
InterCure Reports Surging Revenue, Positive Cash Flow in H1
InterCure reported first-half 2025 revenue of NIS 130 million, its eleventh straight period of positive adjusted EBITDA at 10%...
VIVUS Announces Qsymia Price Reduction at Costco Pharmacies
VIVUS has cut the retail cash price of Qsymia, its phentermine/topiramate extended‑release capsule for chronic weight management, to under...